Brokers Offer Predictions for ALLR Q1 Earnings

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Research analysts at Ascendiant Capital Markets issued their Q1 2027 EPS estimates for shares of Allarity Therapeutics in a report released on Thursday, April 9th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per share of ($0.24) for the quarter. Ascendiant Capital Markets currently has a “Buy” rating and a $9.75 price target on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($78.08) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.24) EPS and FY2027 earnings at ($0.97) EPS.

Allarity Therapeutics (NASDAQ:ALLR) last posted its earnings results on Monday, March 30th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.75.

Allarity Therapeutics Price Performance

NASDAQ ALLR opened at $1.19 on Tuesday. The firm’s fifty day moving average price is $1.06 and its 200 day moving average price is $1.18. The company has a market capitalization of $18.83 million, a price-to-earnings ratio of -1.49 and a beta of 0.01. Allarity Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.35.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Private Advisor Group LLC purchased a new position in Allarity Therapeutics during the 3rd quarter worth $441,000. Renaissance Technologies LLC grew its position in Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after purchasing an additional 181,426 shares during the last quarter. DRW Securities LLC purchased a new position in Allarity Therapeutics during the 4th quarter worth $133,000. Capital Advisors Inc. OK purchased a new position in Allarity Therapeutics during the 4th quarter worth $108,000. Finally, Citadel Advisors LLC purchased a new position in Allarity Therapeutics during the 3rd quarter worth $149,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.